MeSH D007251 - human influenza
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Amantadine | Amantadine |  | 1991-08-23 |  |  |
| Oseltamivir | Oseltamivir |  | 2019-02-27 |  |  | |
| GSK | Zanamivir | Dectova |  | 2019-04-26 |  |  |
| Zanamivir | Relenza |  | 1999-07-26 |  |  | |
| Roche | Oseltamivir | Tamiflu |  | 1999-10-27 | $311.311 M | Y2020 |
| Baloxavir marboxil | Xofluza |  | 2021-01-07 | $46.91 M | Y2020 | |
| Cipla | Amantadine | Amantadine |  | 2016-09-30 |  |  |
| Oseltamivir | Oseltamivir |  | 2023-10-03 |  |  | |
| Lupin Research | Oseltamivir | Oseltamivir |  | 2018-02-20 |  |  |
| Sandoz | Amantadine | Amantadine |  | 1987-02-18 |  |  |
| Xttrium Laboratories | Amantadine | Amantadine |  | 1998-12-24 |  |  |
1
2
3
4
5
6
>
Clinical Trials
Historical Success Rate
Phase 1
57%13/23
Phase 2
73%19/26
Phase 3
55%21/38
Approved: 9Overall Success rate: 23%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
4
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use